行情

PSTI

PSTI

Pluristem疗法
NASDAQ

实时行情|Nasdaq Last Sale

8.97
-0.13
-1.43%
盘后: 8.97 0 0.00% 19:23 08/07 EDT
开盘
9.08
昨收
9.10
最高
9.37
最低
8.84
成交量
43.83万
成交额
--
52周最高
13.29
52周最低
2.820
市值
2.23亿
市盈率(TTM)
-1.1839
分时
5日
1月
3月
1年
5年

分析师评级

5位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测PSTI价格均价为16.10,最高价位25.00,最低价为12.00。

EPS

PSTI 新闻

更多
Pluristem updates on clinical programs
Pluristem Therapeutics' (NASDAQ:PSTI) provides an update on the key clinical milestones and corporate developments. The company expects to announce top lin
seekingalpha · 07/21 16:50
Pluristem CEO Issues Shareholder Update On Clinical Programs; Says Had $59M In Cash And Equivalents As Of Jun. 30
HAIFA, Israel, July 21, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (NASDAQ:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological products, today issued an update
Benzinga · 07/21 11:14
Pluristem CEO Issues Shareholder Update on Clinical Programs
HAIFA, Israel, July 21, 2020 -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological.
GlobeNewswire · 07/21 11:10
Pluristem files for $250M mixed shelf
Pluristem Therapeutics (NASDAQ:PSTI) has filed a prospectus for a $250M mixed shelf offering. Shares down 1% after-hours.
seekingalpha · 07/17 01:55
Pluristem Therapeutics On July 16 Entered Into Open Market Sale Agreement With Jefferies; May Issue And Sell Common Shares Of Up To $75M From Time To Time Through Jefferies
-Reuters
Reuters · 07/16 21:31
Pluristem Therapeutics Inc Files For Mixed Shelf Of Up To $250M
-Reuters
Reuters · 07/16 20:57
Stocks To Watch: Postmates, Walgreens And Cannabis Plays
Seeking Alpha - Article · 07/04 12:17
Pluristem Is a High Risk, High Reward Play, Says Jefferies Analyst
Just how high can Pluristem Therapeutics (PSTI) climb? The Israeli biotech has outperformed in 2020, with shares up by 94% year-to-date. Driving the micro-cap’s forward charge has been a familiar 2020 narrative. The company’s PLX-PAD cell therapy, which uses a
SmarterAnalyst · 06/24 01:24

所属板块

生物技术和医学研究
-0.18%
制药与医学研究
+0.08%

热门股票

代码
价格
涨跌幅

PSTI 简况

Pluristem Therapeutics Inc.是一家开发治疗多发性缺血、炎症和血液病症的胎盘细胞治疗候选产品的开发商。该公司的主要适应症是重症肢体缺血(CLI)、术后股骨颈骨折恢复和急性放射综合征。该公司主要从事细胞治疗与相关技术的研究、开发、临床试验和制造业务。该公司的产品包括PLX-PAD和PLX R18。该公司的PLX细胞是使用三维(3D)过程扩展的贴壁基质细胞(ASC)。该公司的系统利用合成支架创造胎盘基质细胞可以生长的人造3D环境。该公司的PLX产品使用标准针头和注射器进行给药。该公司的PLX产品正处于多种适应症的临床开发阶段,如心血管、骨科、肺部与妇女健康等疾病。
展开

微牛提供Pluristem Therapeutics Inc.(NASDAQ-PSTI)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的PSTI股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易PSTI股票基本功能。